Generic Name: selonsertib
Drug Class: NAFLD/NASH Medications
Company: Gilead Sciences
Approval Status: Experimental
Generic Version Available: No
Experimental Code: GS-4997
General Info
Selonsertib is a small-molecule inhibitor of apoptosis signal-regulating kinase 1 (ASK1) in Phase 3 clinical trials. Gilead announced disappointing results from this study.
Dosage
Dosing Info: N/A
Side Effects
N/A
Last Reviewed: February 21, 2019